Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus
- PMID: 11687105
- DOI: 10.1002/14651858.CD001316
Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus
Update in
-
WITHDRAWN: Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus.Cochrane Database Syst Rev. 2015 Mar 10;2015(3):CD001316. doi: 10.1002/14651858.CD001316.pub2. Cochrane Database Syst Rev. 2015. PMID: 25756659 Free PMC article.
Abstract
Background: Superior vena caval obstruction (SVCO) is an uncommon manifestation of carcinoma of the bronchus characterised by neck swelling and distended veins over the chest. In recent years, the majority of patients with small cell lung cancer (SCLC) with SVCO at diagnosis have tended to receive chemotherapy whilst the majority of patients presenting with non-small cell lung cancer (NSCLC) and SVCO have tended to receive radiotherapy. Steroids may also be prescribed. Stenting now provides a further treatment option which may be combined with radiotherapy and chemotherapy or used on its own. The optimal timing of stenting at present is unclear.
Objectives: To determine the relative effectiveness of treatments currently employed in the management of SVCO.
Search strategy: Electronic searching of Cochrane Clinical Trials register, Medline and Embase. Identification of further studies from references cited in trials identified by electronic searching.
Selection criteria: Both randomised and non-randomised controlled trials in which patients with carcinoma of the bronchus and a diagnosis of SVCO had been treated with any combination of the following treatment modalities: steroids, chemotherapy, radiotherapy or insertion of an expandable metal stent.
Data collection and analysis: There were 3 randomised and 98 non-randomised studies of which 2 and 44 respectively met the inclusion criteria.
Main results: SVCO was present at diagnosis in 10.0% of patients with SCLC and 1.7% of patients with NSCLC. In one randomised trial in SCLC, the rate of SVCO relapse was not significantly reduced by giving radiotherapy on completion of chemotherapy. In the other, in NSCLC, the addition of induction chemotherapy to a course of synchronous chemo-radiotherapy did not increase the rates of relief of SVCO. In SCLC, chemotherapy and/or radiotherapy relieved SVCO in 77%; 17% of those treated had a recurrence of SVCO. In NSCLC, 60% had relief of SVCO following chemotherapy and/or radiotherapy; 19% of those treated had a recurrence of SVCO. Insertion of an SVC stent relieved SVCO in 95%; 11% of those treated had further SVCO but recanalisation was possible in the majority resulting in a long-term patency rate of 92%. Morbidity following stent insertion was greatest if thrombolytics were administered. No study described the effectiveness of steroids in SVCO.
Reviewer's conclusions: Chemotherapy and radiotherapy are effective in relieving SVCO in a proportion of patients whilst stent insertion appears to provide relief in a higher proportion and more rapidly. The optimal timing of stent insertion (whether at diagnosis or following failure of other modalities) is currently uncertain. The effectiveness of steroids in SVCO remains uncertain.
Similar articles
-
Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review.Clin Oncol (R Coll Radiol). 2002 Oct;14(5):338-51. doi: 10.1053/clon.2002.0095. Clin Oncol (R Coll Radiol). 2002. PMID: 12555872
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable).Cochrane Database Syst Rev. 2001;(2):CD002935. doi: 10.1002/14651858.CD002935. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2015 Mar 10;(3):CD002935. doi: 10.1002/14651858.CD002935.pub2. PMID: 11406051 Updated.
-
Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable).Cochrane Database Syst Rev. 2001;(1):CD002935. doi: 10.1002/14651858.CD002935. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2001;(2):CD002935. doi: 10.1002/14651858.CD002935. PMID: 11279780 Updated.
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
Cited by
-
[Small cell lung cancer].Wien Klin Wochenschr. 2007;119(23-24):697-710. doi: 10.1007/s00508-007-0913-1. Wien Klin Wochenschr. 2007. PMID: 18157602 Review. German.
-
Patterns of referral and knowledge of palliative radiotherapy in Alberta.Can Fam Physician. 2012 Feb;58(2):e113-22. Can Fam Physician. 2012. PMID: 22439173 Free PMC article.
-
Anesthetic management of superior vena cava syndrome due to anterior mediastinal mass.J Anaesthesiol Clin Pharmacol. 2012 Apr;28(2):242-6. doi: 10.4103/0970-9185.94910. J Anaesthesiol Clin Pharmacol. 2012. PMID: 22557753 Free PMC article.
-
Superior Vena Cava Syndrome: Etiologies, Manifestations, and Treatments.Semin Intervent Radiol. 2022 Aug 31;39(3):292-303. doi: 10.1055/s-0042-1753480. eCollection 2022 Jun. Semin Intervent Radiol. 2022. PMID: 36062219 Free PMC article. Review.
-
Combination of Palliative Thoracic Radiotherapy With Bevacizumab for Stage IV Nonsquamous NSCLC: Is There Any Impact of Time Interval on Survival?Clin Med Insights Oncol. 2022 Jun 24;16:11795549221106462. doi: 10.1177/11795549221106462. eCollection 2022. Clin Med Insights Oncol. 2022. PMID: 35770233 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous